[Expression of the cerbB-2 (HER-2/neu) oncoprotein in prostatic adenocarcinoma]. / Estudio de la expresión de cerbB-2 en el adenocarcinoma de próstata.

OBJECTIVES: Our aim is to determine the expression of the cerbB-2 oncoprotein in prostate cancers using an immunohistochemistry staining and to compare these results with several clinical and histological prognostic factors. METHODS: An immunohistochemical staining using the cerbB-2 monoclonal antibody (Dako) was performed in 32 radical prostatectomy specimens diagnosed of adenocarcinoma. The intensity of cerbB-2 expression was evaluated with a scale that variated from 0 (no staining) to 3+ (strong complete membrane staining) according to published guidelines. Association of cerbB-2 index immunoreactivity with clinical and histological prognostic factors was examined. RESULTS: Definite positive membranous staining was detected in 14 of 32 neoplastic cases (44%). Such overexpression was correlated with higher Gleason grade (p=0.04) and higher stage of disease (p=0.038). CONCLUSIONS: 1) This study shows that 44% of all prostate cancer express the cerbB-2 oncoprotein with immunohistochemical technique. 2) These findings suggest that is necessary to standardize the immunohistochemical staining procedure with cerbB-2 in prostate adenocarcinoma. 3) The level of cerbB-2 expression was correlated with Gleason grade and clinical stage.

Estudio de la expresión de cerbB-2 en el adenocarcinoma de prostata / Expression of the cerbB-2 (HER-2/neu) oncoprotein in prostatic adenocarcinoma

Objetivos: Determinar la expresión de la oncoproteína cerbB-2 en carcinomas de próstata con técnicas de inmunohistoquímica de próstata y comparar estos resultados con diversos factores pronósticos clínicos e histológicos. Material y métodos: Se realizó tinción inmunohistoquímica con el anticuerpo cerbB-2 (DAKO) en 32 piezas de prostatectomia radical infiltradas por un adenocarcinoma. La expresión de cerbB-2 fue evaluada de 0 (no-tinción) a 3+ (tinción intensa y continua en la membrana celular) según protocolo. Se analizó la asociación estadística entre la expresión de cerbB-2 con algunos parámetros clínicos e histológicos. Resultados: Se demostró positividad de membrana en 14 de las 32 neoplasias evaluadas (44%). La sobreexpresión de cerbB-2 se correlacionó estadísticamente con el índice de Gleason (p=0.04) y estadio clínico (p=0.038). Conclusiones: 1) Nuestro estudio muestra que aproximadamente el 44% de los carcinomas prostáticos expresan cerbB-2 con técnicas de inmunohistoquímica. 2) Esta serie permite deducir la necesidad de estandarizar la técnica inmunohistoquímica de cerbB-2 en el adenocarcinoma prostático. 3) En nuestro trabajo existe asociación estadística significativa de la expresión de cerbB-2, según el método modificado, con el estadío clínico e índice de Gleason

Objectives: Our aim is to determine the expression of the cerbB-2 oncoprotein in prostate cancers using an immunohistochemistry staining and to compare these results with several clinical and histological prognostic factors. Methods: An immunohistochemical staining using the cerbB-2 monoclonal antibody (Dako) was performed in 32 radical prostatectomy specimens diagnosed of adenocarcinoma. The intensity of cerbB-2 expression was evaluated with a scale that variated from 0 (no staining) to 3+ (strong complete membrane staining) according to published guidelines. Association of cerbB-2 index immunoreactivity with clinical and histological prognostic factors was examined. Results: Definite positive membranous staining was detected in 14 of 32 neoplastic cases (44%). Such overexpression was correlated with higher Gleason grade (p=0.04) and higher stage of disease (p=0.038). Conclusions: 1) This study shows that 44% of all prostate cancer express the cerbB-2 oncoprotein with immunohistochemical technique. 2) These findings suggest that is necessary to standardize the immunohistochemical staining procedure with cerbB-2 in prostate adenocarcinoma. 3) The level of cerbB-2 expression was correlated with Gleason grade and clinical stage